Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

丝裂霉素激动剂预防腓骨肌萎缩症 2A

• 批准号: 10253340
• 负责人: Gerald W. Dorn
• 金额: $ 105.92万
• 依托单位: MITOCHONDRIA IN MOTION, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10253340
• 关键词: 20 year old; Address; Agonist; American; Amyotrophic Lateral Sclerosis; Bioavailable; Biological Assay; Biotechnology; Canis familiaris; Cells; Charcot-Marie-Tooth Disease; Chemicals; Child; Childhood; Clinic; Clinical; Clinical Trials; Degenerative Disorder; Development; Diabetic Neuropathies; Disease; Dose; Drug Targeting; Fibroblasts; Follow-Up Studies; Forearm; Formulation; Functional disorder; Funding; Genes; Genetic; Geography; Goals; Government; Grant; Hand; Health; Healthcare; Hour; Human; Huntington Disease; Impairment; In Vitro; Interruption; Lead; Leg; Life; Lower Extremity; Metabolism; Mitochondria; Modeling; Morphology; Motion; Motor; Motor Neurons; Mus; Muscular Atrophy; Muscular Dystrophies; Mutation; Nerve; Nerve Degeneration; Neurodegenerative Disorders; Neurons; Neuropathy; Oral; Oral Administration; Parkinson Disease; Pathology; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Positioning Attribute; Proteins; Publishing; Rare Diseases; Rattus; Research; Resources; Safety; Schedule; Sensory; Small Business Technology Transfer Research; Therapeutic; Therapeutic Index; Toxic effect; Translating; Universities; Upper Extremity; Washington; Wheelchairs; cell motility; chemotherapy; clinical candidate; commercialization; disability; disease diagnosis; disease-causing mutation; efficacy evaluation; first-in-human; foot; improved; in vivo; medical schools; mitochondrial fitness; mutant; nervous system disorder; neuromuscular; non-genetic; novel strategies; patient advocacy group; pharmacokinetics and pharmacodynamics; physical state; pre-clinical; prevent; programs; research and development; response to injury; sciatic nerve; screening; small molecule; therapeutically effective; trafficking; young adult

Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: Charcot-Marie-Tooth (CMT) disease type 2A is an incurable, primarily pediatric, autosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusin (MFN) 2 gene. There are currently no disease-altering treatments. With Phase I STTR support, Mitochondria in Motion, Inc. has developed the first pharmaceutically acceptable small molecule mitofusin activator to treat CMT2A and possibly other neurological diseases. In general, mitofusin activation enhances mitochondrial fitness, metabolism, and trafficking within neurons, thus improving homeostatic functioning and injury-responses. Our clinical lead mitofusin activator, trans-MiM111, normalizes mitochondrial abnormalities in CMT2A patient fibroblasts and reprogrammed neurons in vitro, and reverses neuromuscular dysfunction in mice expressing a human CMT2A MFN2 mutant (T105M) in vivo. During STTR Phase I we validated our hypothesis that activating endogenous, genetically normal MFN2 and MFN1 could reverse dominant inhibition by CMT2A MFN2 mutants of neuronal mitochondrial fusion and trafficking, thus preventing CMT2A-induced neuromuscular degeneration. Having identified a pharmaceutically acceptable clinical candidate, trans-MiM111, our Phase II goals are to define optimal dosing levels and schedule using our CMT2A mouse (SA#1), and initiate GLP (non- GMP) pre-IND studies to position us for FDA approval of first-in-human trials. If we are successful, we will fill an unmet healthcare need and build a commercial enterprise to serve the ~10,000 Americans with CMT2A and the >200,000 Americans suffering from other neurodegenerative diseases characterized by mitochondrial degeneration, including CMT type 1, amyotrophic lateral sclerosis, and Huntington’s disease. Our deliverable for this 2 year Phase II STTR will be a mitofusin activator positioned for FDA approval and phase I, first in human, trials.

丝裂酶激动剂预防腓骨肌萎缩症2A